{
    "clinical_study": {
        "@rank": "3312", 
        "arm_group": [
            {
                "arm_group_label": "Orsiro Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BioMatrix or BioMatrix Flex Arm", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The use of a biodegradable polymer has the potential to reduce the sustained inflammatory\n      response of the arterial wall, facilitating re-endothelialization and minimizing the risk of\n      thrombus formation and late restenosis. In the study, we are going to two biodegradable\n      polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by\n      optical coherence tomography at 3 months after stent implantation.\n\n      The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to\n      Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The\n      secondary endpoint is clinical outcomes up to 1 year."
        }, 
        "brief_title": "Comparison of Biodegradable Stents: Orsiro and BioMatrix", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "All-comer", 
            "Percutaneous Coronary Intervention"
        ], 
        "detailed_description": {
            "textblock": "The use of a biodegradable polymer has the potential to reduce the sustained inflammatory\n      response of the arterial wall, facilitating re-endothelialization and minimizing the risk of\n      thrombus formation and late restenosis. In the study, we are going to two biodegradable\n      polymer stents, Orsiro and BioMatrix, especially regarding the stent strut coverage by\n      optical coherence tomography at 3 months after stent implantation.\n\n      The primary objective of this study is to test the hypothesis that Orsiro is non-inferior to\n      Biomatrix in terms of stent strut coverage by optical coherence tomography at 3 months. The\n      secondary endpoint is clinical outcomes up to 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients \u2265 20 years old\n\n          2. Patients in the treatment of subjects with all-comer who are to undergo PCI\n\n        Exclusion Criteria:\n\n          1. Pregnant women or women with potential childbearing\n\n          2. Life expectancy < 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084901", 
            "org_study_id": "1-2013-0083"
        }, 
        "intervention": [
            {
                "arm_group_label": "Orsiro Arm", 
                "description": "Drug-eluting biodegradable stent Orsiro implantation", 
                "intervention_name": "Drug-eluting biodegradable stent Orsiro implantation", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "BioMatrix or BioMatrix Flex Arm", 
                "description": "Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation", 
                "intervention_name": "Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Biodegradable stents", 
            "converage", 
            "OCT"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "number_of_arms": "2", 
        "official_title": "Comparison of Biodegradable Stents: Orsiro and BioMatrix", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The percentage of stent uncoverage measured by optical coherence tomography", 
            "measure": "Neointimal coverage at 3 month after stent implantation", 
            "safety_issue": "No", 
            "time_frame": "At 3 months after stent implantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}